LENZ Stock Summary and Trading Ideas (Lenz Therapeutics | NASDAQ:LENZ)

LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products. Its products VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours. VIZZ is powered by aceclidine, highlighted by its differentiated mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation.

Lenz Therapeutics trades on the NASDAQ stock market under the symbol LENZ.

As of April 10, 2026, LENZ stock price declined to $9.07 with 486,341 million shares trading.

LENZ has a beta of 2.49, meaning it tends to be more sensitive to market movements. LENZ has a correlation of 0.13 to the broad based SPY ETF.

LENZ has a market cap of $284.38 million. This is considered a Small Cap stock.

Last quarter Lenz Therapeutics reported $2 million in Revenue and -$1.16 earnings per share. This fell short of revenue expectation by $-2 million and missed earnings estimates by -$.25.

The top ETF exchange traded funds that LENZ belongs to (by Net Assets): VTI, IWM, VXF, IBB, IWO.

LENZ has underperformed the market in the last year with a price return of -55.6% while the SPY ETF gained +25.2%. LENZ has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -39.0% and +1.5%, respectively, while the SPY returned -1.8% and +5.3%, respectively.

LENZ support price is $8.77 and resistance is $9.81 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LENZ shares will trade within this expected range on the day.